Oral drug combo tested for rare blood cancer
NCT ID NCT02844309
Summary
This study tested whether a combination of oral medications could help control Waldenström macroglobulinemia, a rare blood cancer. The treatment involved initial therapy with thalidomide, cyclophosphamide, and dexamethasone, followed by long-term maintenance therapy with thalidomide and prednisone. The study enrolled 44 newly diagnosed patients to see how well this approach worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shuhua Yi
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.